BRPI0918513A2 - formas cristalinas de um derivado de 2-tiazolil-4-quinolinil-óxi, seu sal de sódio, suas composições farmacêuticas e seu uso - Google Patents
formas cristalinas de um derivado de 2-tiazolil-4-quinolinil-óxi, seu sal de sódio, suas composições farmacêuticas e seu usoInfo
- Publication number
- BRPI0918513A2 BRPI0918513A2 BRPI0918513A BRPI0918513A BRPI0918513A2 BR PI0918513 A2 BRPI0918513 A2 BR PI0918513A2 BR PI0918513 A BRPI0918513 A BR PI0918513A BR PI0918513 A BRPI0918513 A BR PI0918513A BR PI0918513 A2 BRPI0918513 A2 BR PI0918513A2
- Authority
- BR
- Brazil
- Prior art keywords
- quinolinyloxy
- thiazolyl
- derivative
- pharmaceutical compositions
- sodium salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9729108P | 2008-09-16 | 2008-09-16 | |
US15082609P | 2009-03-09 | 2009-03-09 | |
PCT/US2009/056772 WO2010033444A1 (en) | 2008-09-16 | 2009-09-14 | Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hcv inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0918513A2 true BRPI0918513A2 (pt) | 2015-12-01 |
Family
ID=41268627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0918513A BRPI0918513A2 (pt) | 2008-09-16 | 2009-09-14 | formas cristalinas de um derivado de 2-tiazolil-4-quinolinil-óxi, seu sal de sódio, suas composições farmacêuticas e seu uso |
Country Status (34)
Country | Link |
---|---|
US (2) | US8232293B2 (pt) |
EP (2) | EP2331538B1 (pt) |
JP (2) | JP5520301B2 (pt) |
KR (1) | KR101653550B1 (pt) |
CN (1) | CN102159571B (pt) |
AR (1) | AR073298A1 (pt) |
AU (1) | AU2009293494B2 (pt) |
BR (1) | BRPI0918513A2 (pt) |
CA (1) | CA2737055C (pt) |
CL (1) | CL2011000558A1 (pt) |
CO (1) | CO6351741A2 (pt) |
CY (1) | CY1115253T1 (pt) |
DK (1) | DK2331538T3 (pt) |
EA (1) | EA018603B1 (pt) |
EC (1) | ECSP11010878A (pt) |
ES (1) | ES2474992T3 (pt) |
HK (1) | HK1156624A1 (pt) |
HR (1) | HRP20140666T1 (pt) |
IL (1) | IL210345A (pt) |
MA (1) | MA32633B1 (pt) |
ME (1) | ME01831B (pt) |
MX (1) | MX2011002828A (pt) |
MY (1) | MY153093A (pt) |
NZ (2) | NZ591013A (pt) |
PE (2) | PE20110388A1 (pt) |
PL (1) | PL2331538T3 (pt) |
PT (1) | PT2331538E (pt) |
RS (1) | RS53292B (pt) |
SG (1) | SG189740A1 (pt) |
SI (1) | SI2331538T1 (pt) |
TW (1) | TWI471323B (pt) |
UY (1) | UY32119A (pt) |
WO (1) | WO2010033444A1 (pt) |
ZA (1) | ZA201100096B (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
PE20110388A1 (es) | 2008-09-16 | 2011-07-01 | Boehringer Ingelheim Int | Formas cristalinas de un derivado de peptido como inhibidores de hcv |
JP5539363B2 (ja) | 2008-09-17 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | インターフェロンおよびリバビリンとのhcvns3プロテアーゼ阻害剤の組合せ |
WO2010105181A1 (en) * | 2009-03-13 | 2010-09-16 | University Of Toledo | Minimally invasive collapsible cage |
CA2753657A1 (en) * | 2009-03-19 | 2010-09-23 | Boehringer Ingelheim International Gmbh | Process for preparing sulfonyl quinolines |
EP2427434B1 (en) | 2009-05-05 | 2017-05-31 | Boehringer Ingelheim International GmbH | Process for preparing bromo-substituted quinolines |
PT2451438E (pt) | 2009-07-07 | 2014-03-26 | Boehringer Ingelheim Int | Composição farmacêutica para um inibidor de protease viral da hepatite c |
NZ598465A (en) | 2009-10-30 | 2013-10-25 | Boehringer Ingelheim Int | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
CA2813093A1 (en) * | 2010-09-30 | 2012-04-05 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection |
EP2658859A4 (en) | 2010-12-30 | 2014-07-30 | Enanta Pharm Inc | MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS |
MX2013007698A (es) | 2010-12-30 | 2013-08-15 | Abbvie Inc | Inhibidores de serina proteasa de hepatitis c macrociclicos de fenantridina. |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
CN104383541A (zh) | 2011-10-21 | 2015-03-04 | 艾伯维公司 | 用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法 |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
DK2583680T1 (da) | 2011-10-21 | 2015-01-19 | Abbvie Inc | Mono (PSI-7977) eller kombinationsbehandling af DAA til anvendelse ved behandling af HCV |
PE20141817A1 (es) | 2012-01-12 | 2014-12-17 | Boehringer Ingelheim Int | Formulaciones farmaceuticas estabilizadas de un potente inhibidor de hcv |
JP2015509980A (ja) | 2012-03-14 | 2015-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Hcv−hiv同時感染患者集団のhcv感染症を治療するための併用療法 |
WO2013147750A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
WO2013147749A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient subgenotype populations |
JP2015512900A (ja) | 2012-03-28 | 2015-04-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 特別な患者の遺伝子亜型分集団のhcv感染症を治療するための併用療法 |
UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
WO2014138374A1 (en) | 2013-03-08 | 2014-09-12 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
CN105073758B (zh) | 2013-03-15 | 2017-08-11 | 吉利德科学公司 | 丙型肝炎病毒抑制剂 |
KR20150129005A (ko) * | 2013-03-15 | 2015-11-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 무정형 상태의 hcv 억제제의 고체 경구 투여 제형 |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
CA3022119A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
WO2022107182A1 (en) * | 2020-11-18 | 2022-05-27 | University Of Petra | A composition of fentanyl and fatty acids, and a method of preparation thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0649651B1 (en) | 1993-09-28 | 2000-12-13 | R.P. Scherer GmbH | Soft gelatin capsule manufacture |
AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US20020048610A1 (en) * | 2000-01-07 | 2002-04-25 | Cima Michael J. | High-throughput formation, identification, and analysis of diverse solid-forms |
UY28240A1 (es) * | 2003-03-27 | 2004-11-08 | Boehringer Ingelheim Pharma | Fases cristalinas de un potente inhibidor de la hcv |
CN1791599A (zh) * | 2003-05-21 | 2006-06-21 | 贝林格尔.英格海姆国际有限公司 | 丙型肝炎抑制剂化合物 |
CA2568008C (en) | 2004-05-25 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Process for preparing acyclic hcv protease inhibitors |
PE20110388A1 (es) | 2008-09-16 | 2011-07-01 | Boehringer Ingelheim Int | Formas cristalinas de un derivado de peptido como inhibidores de hcv |
US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
-
2009
- 2009-09-14 PE PE2011000636A patent/PE20110388A1/es not_active Application Discontinuation
- 2009-09-14 NZ NZ591013A patent/NZ591013A/xx not_active IP Right Cessation
- 2009-09-14 JP JP2011527015A patent/JP5520301B2/ja active Active
- 2009-09-14 KR KR1020117004209A patent/KR101653550B1/ko active IP Right Grant
- 2009-09-14 SG SG2013024864A patent/SG189740A1/en unknown
- 2009-09-14 NZ NZ602163A patent/NZ602163A/xx not_active IP Right Cessation
- 2009-09-14 EA EA201100482A patent/EA018603B1/ru not_active IP Right Cessation
- 2009-09-14 CN CN200980136131.XA patent/CN102159571B/zh not_active Expired - Fee Related
- 2009-09-14 ME MEP-2014-43A patent/ME01831B/me unknown
- 2009-09-14 EP EP09792493.0A patent/EP2331538B1/en active Active
- 2009-09-14 BR BRPI0918513A patent/BRPI0918513A2/pt not_active Application Discontinuation
- 2009-09-14 RS RS20140230A patent/RS53292B/en unknown
- 2009-09-14 EP EP13188665.7A patent/EP2687526A1/en not_active Withdrawn
- 2009-09-14 PT PT97924930T patent/PT2331538E/pt unknown
- 2009-09-14 AU AU2009293494A patent/AU2009293494B2/en not_active Ceased
- 2009-09-14 PE PE2012002419A patent/PE20130307A1/es active IP Right Grant
- 2009-09-14 CA CA2737055A patent/CA2737055C/en not_active Expired - Fee Related
- 2009-09-14 MY MYPI20111140 patent/MY153093A/en unknown
- 2009-09-14 WO PCT/US2009/056772 patent/WO2010033444A1/en active Application Filing
- 2009-09-14 MX MX2011002828A patent/MX2011002828A/es active IP Right Grant
- 2009-09-14 PL PL09792493T patent/PL2331538T3/pl unknown
- 2009-09-14 SI SI200930919T patent/SI2331538T1/sl unknown
- 2009-09-14 DK DK09792493.0T patent/DK2331538T3/da active
- 2009-09-14 ES ES09792493.0T patent/ES2474992T3/es active Active
- 2009-09-15 TW TW98131069A patent/TWI471323B/zh not_active IP Right Cessation
- 2009-09-15 US US12/559,927 patent/US8232293B2/en active Active
- 2009-09-15 AR ARP090103540A patent/AR073298A1/es not_active Application Discontinuation
- 2009-09-15 UY UY0001032119A patent/UY32119A/es not_active Application Discontinuation
-
2010
- 2010-12-29 IL IL210345A patent/IL210345A/en active IP Right Grant
-
2011
- 2011-01-04 ZA ZA2011/00096A patent/ZA201100096B/en unknown
- 2011-03-09 EC EC2011010878A patent/ECSP11010878A/es unknown
- 2011-03-14 MA MA33699A patent/MA32633B1/fr unknown
- 2011-03-16 CO CO11032830A patent/CO6351741A2/es not_active Application Discontinuation
- 2011-03-16 CL CL2011000558A patent/CL2011000558A1/es unknown
- 2011-10-17 HK HK11111031.5A patent/HK1156624A1/xx not_active IP Right Cessation
-
2012
- 2012-07-03 US US13/541,158 patent/US8362035B2/en active Active
-
2013
- 2013-12-09 JP JP2013253812A patent/JP2014062116A/ja not_active Withdrawn
-
2014
- 2014-07-11 CY CY20141100526T patent/CY1115253T1/el unknown
- 2014-07-14 HR HRP20140666AT patent/HRP20140666T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0918513A2 (pt) | formas cristalinas de um derivado de 2-tiazolil-4-quinolinil-óxi, seu sal de sódio, suas composições farmacêuticas e seu uso | |
BRPI0818193A2 (pt) | composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto | |
BRPI1008793A2 (pt) | composto, uso de um composto, e, composição farmacêutica | |
BRPI1016219A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
BRPI0919942A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
BRPI0907562A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
BRPI0921375A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
BRPI1010621A2 (pt) | derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso | |
BRPI0810696A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
BRPI0810161A2 (pt) | Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto | |
BRPI1007018A2 (pt) | composto, composição farmacêutica, e , uso de um composto. | |
BRPI0912356A2 (pt) | compostos moduladores de sirtuína, composição farmacêutica compreendendo os mesmos e seu uso | |
BR112014001255A2 (pt) | composto, uso de um composto, combinação, e, composição farmacêutica | |
BRPI1008906A2 (pt) | composto, composição farmacêutica, e, uso de um composto. | |
BRPI0921879A2 (pt) | composto, composição farmacêutica , e, uso de um composto | |
BR112014013760A2 (pt) | composto, composição farmacêutica e uso de um composto | |
BR112013008259A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
BRPI0917579A2 (pt) | composto, composição farmacêutica, métodos, e, uso de um composto | |
BRPI1013988A2 (pt) | composto, composição farmacêutica , e, uso de um composto ou um sal farmacologicamente aceitável do mesmo | |
CL2008000403A1 (es) | Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos. | |
BR112014005669A2 (pt) | composto, composição farmacêutica e uso de um composto | |
BRPI0810019A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
BRPI0915120A2 (pt) | composto derivado de oxima, uso do referido composto e composição farmacêutica | |
BR112014003567A2 (pt) | composto, uso de um composto, e, composição farmacêutica | |
BRPI0906937A2 (pt) | composto, composição farmacêutica, e, uso de um composto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |